Supernus Pharmaceuticals, Inc. (SUPN) Financials

EPS

Hollow marker is the consensus estimate; filled is the reported figure, colored by beat or miss.

Revenue

Outlined bar is the consensus estimate; solid is reported.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
Q2 26	$0.51	$0.53	+3.9%	—	$219.1M	—
Q1 26	$0.28	$0.21	-25.0%	—	$207.7M	—
Q4 25	$0.28	$0.88	+214.3%	—	$211.6M	—
Q3 25	$0.82	$0.61	-25.6%	—	$192.1M	—
Q2 25	$0.47	$0.91	+93.6%	—	$165.5M	—
Q1 25	$0.37	$0.44	+18.9%	—	$149.8M	—
Q4 24	$0.52	$0.55	+5.8%	—	$174.2M	—
Q3 24	$0.44	$1.1	+150.0%	—	$175.7M	—
Q2 24	$0.39	$0.67	+71.8%	—	$168.3M	—
Q1 24	$0.38	$0.24	-36.8%	—	$143.6M	—
Q4 23	$0.55	$0.89	+61.8%	—	$164.3M	—
Q3 23	$0.08	$0.24	+200.0%	—	$153.9M	—
Q2 23	-$0.23	-$0.02	+91.3%	—	$135.6M	—
Q1 23	$0.17	$0.29	+70.6%	—	$153.8M	—
Q4 22	$0.68	$0.43	-36.8%	—	$167.3M	—
Q3 22	$0.36	$0.03	-91.7%	—	$177.4M	—

EPS

Reported per-share earnings by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Revenue

Reported revenue by fiscal year; the line turns dotted where reported figures end and the analyst consensus begins, with the shaded band marking the low–high range.

Results

Periods without a consensus estimate or a reported figure show a dash.

Period	EPS estimate	EPS actual	EPS surprise %	Revenue estimate	Revenue actual	Revenue surprise %
FY25	—	-$0.68	—	—	$719M	—
FY24	—	$1.34	—	—	$661.8M	—
FY23	—	$0.02	—	—	$607.5M	—
FY22	—	$1.13	—	—	$667.2M

Total revenue

Reported revenue per period; the line is the change from the same period a year earlier, on its own left axis.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$215M	$302.2M	$408.9M	$392.8M	$520.4M	$579.8M	$667.2M	$607.5M	$661.8M	$719M
YoY change	+45.8%	+40.6%	+35.3%	-3.95%	+32.5%	+11.4%	+15.1%	-8.95%	+8.94%	+8.63%

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	215M	302.2M	408.9M	392.8M	520.4M	579.8M	667.2M	607.5M	661.8M	719M
Cost of revenue	12M	15.2M	15.4M	16.7M	52.5M	75.1M	87.2M	83.8M	77.9M	74.6M
Gross profit	203M	287M	393.5M	376.1M	467.9M	504.7M	580M	523.7M	583.9M	644.4M
Gross margin	94.4%	95%	96.2%	95.8%	89.9%	87.1%	86.9%	86.2%	88.2%	89.6%
Research & development	42.8M	49.6M	89.2M	69.1M	76M	90.5M	74.6M	91.6M	108.8M	106.2M
Selling, general & administrative	106M	137.9M	154.7M	153.2M	200.7M	304.8M	377.2M	336.4M	321.6M	485.6M
Operating expenses	148.8M	187.5M	243.9M	222.3M	276.6M	395.2M	451.8M	428M	430.4M	591.8M
Operating income	54.2M	99.5M	144.4M	148.6M	175.6M	79.5M	45.6M	13.4M	75.6M	-36.9M
Operating margin	25.2%	32.9%	35.3%	37.8%	33.7%	13.7%	6.84%	2.21%	11.4%	-5.13%
Non-operating income, net	-223K	-219K	—	—	-1.9M	6.5M	510K	-18.7M	6.1M	-25.4M
Pretax income	50.4M	100.6M	140.2M	147.5M	168.6M	73.2M	60.7M	2.8M	97.9M	-49M
Income tax	-40.9M	43.3M	29.2M	34.4M	41.7M	19.8M	32K	1.5M	24M	-10.5M
Net income	91.2M	57.3M	111M	113.1M	127M	53.4M	60.7M	1.3M	73.9M	-38.5M
Net margin	42.4%	19%	27.1%	28.8%	24.4%	9.21%	9.1%	0.22%	11.2%	-5.36%
EBITDA	58.1M	110.3M	165.3M	176.9M	212.4M	122.7M	152.8M	108.7M	172.2M	68M
EPS	1.84	1.13	2.13	2.16	2.41	1.01	1.13	0.02	1.34	-0.68
Diluted EPS	1.76	1.08	2.05	2.1	2.36	0.98	1.04	0.02	1.32	-0.68

Revenue and profits

Revenue, gross profit, operating income, and net income per period.

Condensed income statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	153.9M	164.3M	143.6M	168.3M	175.7M	174.2M	149.8M	165.5M	192.1M	211.6M	207.7M	219.1M
Cost of revenue	19.6M	19.6M	16.3M	17.9M	17.6M	26.1M	15.8M	16.8M	19M	23M	23.4M	33.7M
Gross profit	134.3M	144.7M	127.3M	150.4M	158.1M	148.1M	134.1M	148.6M	173.1M	188.6M	184.3M	185.4M
Gross margin	87.3%	88.1%	88.6%	89.4%	90%	85%	89.5%	89.8%	90.1%	89.1%	88.7%	84.6%
Research & development	22.7M	23.3M	24.9M	26.2M	29M	28.6M	26.9M	22.1M	29.4M	27.8M	39.4M	29.5M
Selling, general & administrative	82.7M	81.3M	86.5M	85.9M	69.8M	79.4M	89.9M	93.6M	179.7M	122.4M	125.2M	133.6M
Operating expenses	105.4M	104.6M	111.4M	112.1M	98.8M	108.1M	116.9M	115.7M	209M	150.2M	164.6M	163.1M
Operating income	7.7M	19M	-4.2M	18.2M	39.8M	21.8M	-2.6M	12.1M	-60.2M	13.8M	-5.9M	-3M
Operating margin	4.99%	11.6%	-2.96%	10.8%	22.7%	12.5%	-1.73%	7.34%	-31.4%	6.53%	-2.86%	-1.39%
Non-operating income, net	456K	-20M	1.1M	4.4M	1M	-356K	-7.7M	—	—	-17.8M	-2.4M	-54.9M
Pretax income	9.9M	990K	243K	26.3M	44.9M	26.4M	-5.8M	16.7M	-58M	-1.9M	-6M	-57.6M
Income tax	25.9M	-185K	119K	6.4M	6.4M	11.1M	6M	-5.8M	-12.8M	2.2M	-3.7M	723K
Net income	-16M	1.2M	124K	19.9M	38.5M	15.3M	-11.8M	22.5M	-45.1M	-4.1M	-2.3M	-58.4M
Net margin	-10.4%	0.72%	0.09%	11.8%	21.9%	8.8%	-7.89%	13.6%	-23.5%	-1.94%	-1.1%	-26.6%
EBITDA	31.3M	42.7M	19.9M	42.7M	64M	45.6M	25.4M	33.5M	-35.4M	44.4M	22.6M	25.3M
EPS	-0.29	—	0	0.36	0.7	0.28	-0.21	0.4	-0.8	-0.07	-0.04	-1.01
Diluted EPS	-0.29	—	0	0.36	0.69	0.27	-0.21	0.4	-0.8	-0.07	-0.04	-1.01

P/E

Annual history by fiscal year; click a table row below to chart a different metric.

Current values are trailing twelve months where available, otherwise the latest fiscal year; unreported figures show a dash.

Key stats

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Market cap	1.2B	2B	1.7B	1.2B	1.3B	1.5B	1.9B	1.6B	2B	2.8B	2.6B
Enterprise value	1.2B	1.9B	1.7B	1.3B	1.3B	1.6B	1.9B	1.4B	1.6B	2.5B	2.1B
Shares outstanding	49.5M	50.8M	52M	52.4M	52.6M	53.1M	53.7M	54.5M	55.1M	56.5M	56.5M

Valuation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
P/E	13.7	35.3	15.6	11	10.4	29	31.5	1.2K	27	—	40.7
P/S	5.81	6.69	4.22	3.17	2.54	2.67	2.87	2.6	3.01	3.9	2.99
P/B	6.51	7.56	3.81	2.09	1.78	1.9	2.16	1.71	1.92	2.64	2.41
EV/EBITDA	20	17.1	10.3	7.21	6.19	13.3	12.4	12.6	9.14	37.3	19.4
EV/Sales	5.41	6.23	4.16	3.25	2.53	2.82	2.84	2.25	2.38	3.53	2.59
Earnings yield	7.3%	2.83%	6.43%	9.09%	9.59%	3.45%	3.17%	0.08%	3.71%	—	2.46%
FCF yield	5.22%	5.57%	7.42%	11.4%	10.2%	8.08%	6.08%	7%	8.59%	1.64%	3.26%
PEG	—	—	—	—	—	—	—	—	—	—	-0.12

Profitability

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Gross margin	94.4%	95%	96.2%	95.8%	89.9%	87.1%	86.9%	86.2%	88.2%	89.6%	84.6%
Operating margin	25.2%	32.9%	35.3%	37.8%	33.7%	13.7%	6.84%	2.21%	11.4%	-5.13%	-2.48%
Net margin	42.4%	19%	27.1%	28.8%	24.4%	9.21%	9.1%	0.22%	11.2%	-5.36%	-13.2%
ROE	47.6%	21.4%	24.5%	19%	17%	6.55%	6.85%	0.14%	7.13%	-3.63%	-10.5%
ROA	29.5%	13.5%	11.4%	9.74%	8.44%	3.16%	3.57%	0.1%	5.4%	-2.65%	0.39%
ROIC	51.2%	44.5%	26.8%	18.2%	17.9%	6.43%	5.24%	0.9%	9.25%	-4.64%	-7.92%
Return on tangible assets	38.5%	16.3%	12.1%	10.2%	20.5%	-46.3%	95.5%	-0.84%	81.9%	-60.3%	-43.9%

Financial health

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Current ratio	1.88	1.86	3.06	2.94	2.57	1.91	1.07	1.7	2.35	1.9	2.08
Quick ratio	1.67	1.72	2.9	2.78	2.37	1.63	0.93	1.43	2.16	1.66	1.84
Debt / equity	0.02	0	0.73	0.64	0.56	0.52	0.5	0.05	0.03	0.04	0.04
Debt / assets	0.01	0	0.34	0.33	0.28	0.25	0.26	0.03	0.03	0.03	0.03
Net debt / EBITDA	-1.48	-1.27	-0.16	0.18	-0.04	0.71	-0.11	-1.96	-2.44	-3.94	-5.83
Interest coverage	10.9	65.2	8.74	7.5	8.1	4.12	9.59	2.15	—	—	—
Effective tax rate	0%	43.1%	20.8%	23.3%	24.7%	27%	0.05%	52.5%	24.5%	0%	0%

Per share

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Revenue per share	4.35	5.95	7.86	7.49	9.89	10.9	12.4	11.1	12	12.7	14.5
EPS (basic)	1.84	1.13	2.13	2.16	2.41	1.01	1.13	0.02	1.34	-0.68	-0.68
EPS (diluted)	1.76	1.08	2.05	2.1	2.36	0.98	1.04	0.02	1.32	-0.68	-1.92
Book value per share	3.88	5.27	8.71	11.4	14.2	15.4	16.5	16.9	18.8	18.8	17.7
FCF per share	1.32	2.22	2.46	2.7	2.56	2.36	2.17	2.03	3.11	0.81	0.32
Cash per share	1.82	2.76	6.85	6.62	8.03	6.4	8.6	4.67	8.23	5.47	6.4
Capex per share	0.03	0.04	0.02	0.03	0.07	0.04	0.01	0.01	0.01	—	—

Capital allocation

Metric	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25	Current
Capex / revenue	0.75%	0.67%	0.21%	0.35%	0.71%	0.35%	0.06%	0.09%	0.11%	—	—
Capex / operating cash flow	3.88%	2.77%	0.89%	0.96%	2.53%	1.56%	0.5%	0.62%	0.44%	—	—
Payout ratio	—	—	—	—	—	—	—	—	—	—	0%

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Revenue	$153.9M	$164.3M	$143.6M	$168.3M	$175.7M	$174.2M	$149.8M	$165.5M	$192.1M	$211.6M	$207.7M	$219.1M
YoY change	-13.2%	-1.8%	-6.58%	+24.2%	+14.2%	+5.99%	+4.3%	-1.71%	+9.34%	+21.5%	+38.6%	+32.4%

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & short-term investments	90.1M	140M	356M	347.1M	422.5M	339.7M	461.3M	254.9M	453.6M	308.7M
Receivables	41.5M	65.6M	102.9M	87.3M	140.9M	148.9M	165.5M	144.2M	142.1M	187.8M
Inventory	16.8M	16.3M	25.7M	26.6M	48.3M	86M	91.5M	77.4M	54.3M	82.4M
Total current assets	151.4M	228.5M	493.5M	472.6M	630.4M	601.6M	734.2M	493.1M	686.1M	644.2M
Property, plant & equipment	11.1M	13.5M	13.1M	28.1M	37.8M	29.2M	27.3M	13.5M	11.5M	10.5M
Goodwill & intangibles	72.7M	72M	62.7M	49.7M	884.5M	1.8B	1.6B	1.4B	1.3B	1.4B
Total assets	309.6M	424.5M	977.8M	1.2B	1.5B	1.7B	1.7B	1.3B	1.4B	1.5B
Accounts payable	8.1M	6.8M	3.2M	10.1M	6.1M	9.3M	10.5M	2M	4.6M	2.7M
Short-term debt	—	—	—	2.8M	3.8M	6.5M	408.8M	8.3M	6.9M	10.6M
Total current liabilities	80.7M	123M	161.4M	160.6M	245.1M	315.4M	688M	290.2M	292.4M	338.2M
Long-term debt	4.2M	0	329.5M	375.6M	410.6M	420.6M	36M	33.2M	27.4M	30.4M
Total liabilities	117.8M	157M	524.8M	564.9M	759.2M	873.3M	816.3M	356.2M	332.3M	390.9M
Shareholders' equity	191.8M	267.5M	453M	595.4M	744.9M	815.9M	886.2M	921.5M	1B	1.1B
Total debt	4.2M	0	329.5M	378.4M	414.3M	427M	444.8M	41.5M	34.3M	41M
Net debt	-62.2M	-100.3M	137.2M	197.1M	125.7M	223.6M	351.6M	-33.5M	-35.1M	-87.5M

Assets vs. liabilities & equity

What the company owns (left stack) against what it owes plus shareholders' equity (right stack). The two stacks should match — that's the balance.

Condensed balance sheet

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Cash & short-term investments	200.2M	254.9M	297.7M	347.2M	403.2M	453.6M	463.6M	522.6M	281.2M	308.7M	384.2M	372.1M
Receivables	141.8M	144.2M	147.7M	152.5M	145.4M	142.1M	145.6M	140.8M	171.3M	187.8M	182.2M	211.7M
Inventory	83.5M	77.4M	75.1M	68.2M	64M	54.3M	49.4M	44M	79.4M	82.4M	87.1M	83.9M
Total current assets	449.4M	493.1M	544.3M	591M	640M	686.1M	687.6M	738.9M	593.9M	644.2M	731.6M	723.5M
Property, plant & equipment	13.7M	13.5M	13M	12.3M	11.9M	11.5M	11.3M	11.1M	10.6M	10.5M	10M	10.2M
Goodwill & intangibles	1.5B	1.4B	1.4B	1.4B	1.3B	1.3B	1.2B	1.2B	1.5B	1.4B	1.3B	1.2B
Total assets	1.3B	1.3B	1.3B	1.3B	1.3B	1.4B	1.3B	1.4B	1.4B	1.5B	1.5B	1.4B
Accounts payable	3.4M	2M	14.4M	4.6M	6.4M	4.6M	7.1M	8.2M	8.2M	2.7M	10.2M	5.6M
Short-term debt	8.5M	8.3M	9.1M	9.7M	9.2M	6.9M	5.9M	7.4M	10.8M	10.6M	10.6M	10.7M
Total current liabilities	287.5M	290.2M	314.6M	308.7M	291.5M	292.4M	281.8M	286.4M	330.6M	338.2M	373.9M	347.4M
Long-term debt	33.8M	33.2M	33M	30.3M	28.9M	27.4M	26.4M	24.4M	31.4M	30.4M	30.3M	29.4M
Total liabilities	373M	356.2M	374.9M	358.4M	335.6M	332.3M	316.6M	318.5M	370.1M	390.9M	423.9M	396.9M
Shareholders' equity	912.2M	921.5M	929.2M	957.5M	1B	1B	1B	1.1B	1B	1.1B	1.1B	1B
Total debt	42.3M	41.5M	42.1M	40M	38.2M	34.3M	32.3M	31.8M	42.2M	41M	40.9M	40.2M
Net debt	-52.7M	-33.5M	-21.3M	-12.1M	6.5M	-35.1M	-83.5M	-112.9M	-109.2M	-87.5M	-144M	-139.8M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	FY16	FY17	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Net income	91.2M	57.3M	111M	113.1M	127M	53.4M	60.7M	1.3M	73.9M	-38.5M
Depreciation & amortization	2.4M	8.1M	7.1M	6.7M	18.1M	32.6M	85.5M	84.9M	80.4M	91.6M
Stock-based compensation	5.9M	8.4M	11.3M	14.8M	16.6M	17.9M	17.6M	26.8M	27.8M	33.1M
Change in working capital	-16.6M	-17.9M	-40.3M	-2.1M	-36.5M	7.5M	-55.5M	-11.4M	2.9M	-54.4M
Operating cash flow	41.3M	73.3M	95.1M	144.5M	145.7M	131M	82.4M	88.7M	166.2M	47.3M
Capital expenditure	-1.6M	-2M	-844K	-1.4M	-3.7M	-2M	-412K	-551K	-725K	—
Investing cash flow	-36M	-86.4M	-413.5M	-156.6M	-19.9M	-94.8M	-216.7M	268.7M	-189.9M	5.4M
Dividends paid	—	—	—	—	—	—	—	—	—	—
Share repurchases	—	—	—	—	—	—	—	—	—	—
Financing cash flow	2.1M	5.7M	310.8M	3.9M	3.6M	-130.4M	-10.5M	-893.4M	12.2M	9.1M
Net change in cash	7.4M	-7.4M	-7.6M	-8.1M	129.3M	-94.3M	-144.8M	-535.9M	-11.5M	61.9M
Free cash flow	65.2M	112.6M	128.1M	141.7M	134.7M	125.1M	116.4M	110.5M	171.2M	46M

Cash generation and uses

Cash from operations, what's left after capex, and what went back to shareholders. Bars below the line are cash going out.

Condensed cash flow statement

Click a row to chart it; unreported figures show a dash.

Period	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Net income	-16M	1.2M	124K	19.9M	38.5M	15.3M	-11.8M	22.5M	-45.1M	-4.1M	-2.3M	-58.4M
Depreciation & amortization	21.9M	21.7M	20.7M	20.7M	20.1M	18.8M	20.4M	21.4M	24.8M	25M	26.1M	25.7M
Stock-based compensation	7.9M	6.4M	5.9M	6.6M	7.7M	7.6M	8.1M	7.5M	7.8M	9.7M	8.5M	8.6M
Change in working capital	-4.4M	2.4M	8.4M	-11.5M	-137K	6.1M	5.1M	3.2M	-41.6M	-21.1M	5.6M	-33.6M
Operating cash flow	1.8M	24.4M	31.1M	28.1M	62.3M	47.4M	22.3M	58.5M	-61.7M	19.9M	66.5M	-4.8M
Capital expenditure	-150K	36K	-248K	-64K	-200K	-213K	-327K	—	—	—	—	—
Investing cash flow	34.6M	-66M	-51.6M	-48.6M	-77M	-12.6M	37.3M	-30.2M	341.9M	-50.9M	-19.2M	7.7M
Dividends paid	—	—	—	—	—	—	—	—	—	—	—	—
Share repurchases	—	—	—	—	—	—	—	—	—	—	—	—
Financing cash flow	-402.7M	3.1M	1.6M	1.7M	3.1M	5.9M	-21.4M	935K	21.1M	8.5M	9.1M	-7.2M
Net change in cash	-366.3M	-38.5M	-19M	-18.8M	-11.6M	40.7M	38.2M	29.3M	301.3M	-22.5M	56.4M	-4.3M
Free cash flow	35.7M	45M	38.2M	35.6M	53.3M	44.2M	30.3M	58.1M	-61.8M	19.4M	66.5M	-5.4M

Supernus Pharmaceuticals, Inc. Financials

EPS

Revenue

Results

EPS

Revenue

Results

Total revenue

Total revenue

Revenue and profits

Condensed income statement

Revenue and profits

Condensed income statement

P/E

Key stats

Valuation

Profitability

Financial health

Per share

Capital allocation

Assets vs. liabilities & equity

Condensed balance sheet

Assets vs. liabilities & equity

Condensed balance sheet

Cash generation and uses

Condensed cash flow statement

Cash generation and uses

Condensed cash flow statement